Pluri (PLUR) News Mentions Statistics 2025

10%

1W 0% 1M 0% 3M 0%

Est. daily news mentions.

Similar companies

Company		News Mentions
	Amgen AMGN	1 0%
	Gilead Sciences GILD	0 0%
	Catalyst Pharmaceuticals CPRX	2 0%
	Inovio Pharmaceuticals INO	0 0%
	Anavex Life Sciences AVXL	0 0%

Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition

January 23

Comparing Pluri (NASDAQ:PLUR) & Adverum Biotechnologies (NASDAQ:ADVM)

January 15

Financial Contrast: Anavex Life Sciences (NASDAQ:AVXL) and Pluri (NASDAQ:PLUR)

January 14

Pluri (NASDAQ:PLUR) versus Gilead Sciences (NASDAQ:GILD) Financial Contrast

January 8

Head-To-Head Analysis: Evaxion Biotech A/S (NASDAQ:EVAX) versus Pluri (NASDAQ:PLUR)

January 1

Pluri (NASDAQ:PLUR) Stock Price Down 2.8% – Here’s What Happened

December 25

Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

December 18

Carthage's Troubles

March 25

U.S. Intervenes as Indigenous Guatemalans Back President-elect Arévalo

February 10

Mesenchymal Stem Cells/Medicinal Signaling Cells (MSCs) Advances & Applications Report 2025: Comprehensive Analysis Reveals 125 Leading Competitors in MSC Research, Therapeutics and Market Expansion

January 7

Month over Month

Est. daily news mentions.

Mar 2025	0	9.7%
Feb 2025	0	72.3%
Jan 2025	0	300%
Dec 2024	0
Nov 2024	0	0%

How often is Pluri mentioned in the news?

Pluri was mentioned an estimated 1 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Pluri performing compared to its industry peers?

Pluri underperforms its industry peers when it comes to News Mentions, ranking in the 25th percentile.

Has there been an increase or decrease in news mentions of Pluri in the last month?

There has been no significant change in the number of news mentions for Pluri's compared to the last month.

Why is it important to track news mentions for Pluri?

By monitoring mentions in the news for Pluri, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Pluri, ultimately improving their investment strategies.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

Top Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact

Pluri (PLUR) - News Mentions

Similar companies

Amgen

Gilead Sciences

Catalyst Pharmaceuticals

Inovio Pharmaceuticals

Anavex Life Sciences

Pluri Inc. (NASDAQ:PLUR) Short Interest Update

Critical Review: Prime Medicine (NYSE:PRME) and Pluri (NASDAQ:PLUR)

Pluri announces USPTO issued patent covering its immune cell expansion tech

Comparing Kyverna Therapeutics (NASDAQ:KYTX) & Pluri (NASDAQ:PLUR)